T. Wilkinson (Southampton, United Kingdom), J. Roig (Escaldes, Andorra)
Causing pathogenes in the severest AECOPD – one year analysis R. Erzen, E. Music, N. Bajrovic, P. Kopac, V. Tomic, T. Ovcaricek (Golnik, Slovenia)
| |
Individual variation in the levels of procalcitonin, neopterin, CRP and MR-proANP during a COPD exacerbation and clinical stable state A. Lacoma, C. Prat, J. Domínguez, F. Andreo, M. A. Cuesta, J. Ruiz-Manzano, V. Ausina (Badalona, Spain)
| |
Analysis of the causes for the frequent exacerbations and hospitalisations in patients with COPD M. Peneva, Y. Ilieva, B. Drumev (Varna, Bulgaria)
| |
Antibiotics in acute exacerbations of chronic obstructive pulmonary disease A. Fremault, S. Pérez-Bogerd, M. Laurent, G. Celis, J. Wim, D. Marc (Leuven, Belgium)
| |
Inhalation antibacterial therapy of COPD acute exacerbation M. Nefedova, L. Sokolova, E. Shmelev (Moscow, Russian Federation)
| |
Change of biochemical parameters of sputum in patients with different types of COPD exaserbation O. Myronenko, O. Plekhanova, O. Lykholat (Dniepropetrovsk, Dnipropetrovsk, Ukraine)
| |
Atypical respiratory pathogens in severe COPD exacerbations F. Diamantea, A. Nakou, J. Papaparaskevas, F. Drakopanagiotakis, E. Kastanakis, N. Karagiannidis, V. Polychronopoulos (Athens, Greece)
| |
Cytokines profile of blood and sputum in COPD exacerbation S. Nesterovich, E. Bukreeva (Tomsk, Russian Federation)
| |
Does the infection influence on induced sputum cell count at smokers and nonsmokers with COPD exacerbation? S. Nesterovich, E. Bukreeva (Tomsk, Russian Federation)
| |
Cellular peculiarities of bronchial brush-biopsies in dependence on infectional agent species at COPD exacerbation S. Nesterovich, E. Bukreeva (Tomsk, Russian Federation)
| |
Peculiarities of brush-biopsies of bronchial mucosa at different aetiology of COPD exacerbation S. Nesterovich, E. Bukreeva (Tomsk, Russian Federation)
| |
Airway microbial and polymicrobial load in COPD J. Goldring, G. Donaldson, J. Quint, R. Baghai-Ravary, J. Wedzicha (London, United Kingdom)
| |
Budesonide is not associated with increased risk of pneumonia in COPD patients D. Sin, D. Tashkin, X. Zhang, F. Radner, U. Sjobring, A. Thoren, P. M. A. Calverley, S. Rennard (Vancouver, Canada; Los Angeles, Omaha, United States Of America; Lund, Sweden; Liverpool, United Kingdom)
| |
Long term treatment with azithromycin tablets or extended release forms in patients with bronchiectasis M. Zlatev Ionescu, O. Nicolaescu, E. Ciomu, L. Popescu, M. Carstea, M. Nica, E. Ceausu, P. I. Calistru, I. Apostol, A. Kosa (Bucarest, Romania)
| |
24 hour versus early morning spontaneous sputum collection for routine microbiology in stable bronchiectasis M. Murray, C. Doherty, J. Govan, A. Hill (Edinburgh, United Kingdom)
| |
Microbiological follow-up of patients with non-CF bronchiectasis related to exacerbation frequency, pulmonary function tests (PFT) and HRCT-score J. Altenburg, C. O. Martins Jarnalo, W. G. Boersma (Alkmaar, Netherlands)
| |
A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis M. Murray, J. Pentland, A. Hill (Edinburgh, United Kingdom)
| |
Relationship of FEV1 and exercise capacity in stable bronchiectasis M. Murray, A. Hill (Edinburgh, United Kingdom)
| |
Lung function in patients with bronchiectasis is preserved by periodical treatment with antibiotics F. C. Trudzinski, T. Kramm, M. Ulrich, A. Gröschel, G. W. Sybrecht (Homburg/Saar, Germany)
| |
Non cystic fibrosis (CF) bronchiectasis (BE): assessment in a district general hospital in a district general hospital A. Pillai, A. White (Gloucester, United Kingdom)
| |